Program
DA-020
A development code. Also written as “DA-020 (0.1%)”, “DA-020 (0.2%)” and “DA-020 (0.5%)”.
Its studies are mostly in Alopecia, led by Applied Biology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Applied Biology | 21 open or running | phase 2since Feb 2, 2026 | Feb 2, 2026 | Feb 5, 2027phase 2 · NCT07397325 |
Also a collaborator on its studies: Daniel Alain and Follea International.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 2, 2026First study: early phase 1 study in Chemotherapy Induced AlopeciaFirst studyNCT07402330 · Brazil, Italy
- Feb 2, 2026Phase 2 study in Chemotherapy Induced AlopeciaNCT07397325 · 60 planned · Brazil, Italy
- Nov 2, 2026Early phase 1 study withdrawnStudy stoppedNCT07402330 · “Change of protocol moved to new study”
Ahead
- Feb 5, 2027Primary completion: phase 2 study in Chemotherapy Induced AlopeciaNCT07397325
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07402330Chemotherapy Induced Alopecia · Brazil, Italy | Early 1 | Withdrawn | Oct 19, 2026 | 0 |
| NCT07397325Chemotherapy Induced Alopecia · Brazil, Italy | 2 | Recruiting | Feb 5, 2027 | 60 |
How it is read
Names in the registry
- “DA-020 (0.1%)”, 1 entry
- “DA-020 (0.2%)”, 1 entry
- “DA-020 (0.5%)”, 1 entry
- “DA-020”, 1 entry
- “DA-020 and Hyperforin”, 1 entry
Codes read as this program: DA020.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.